May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
The Effect of L–Thyroxine Supplementation on Retinal Vascular Development in Neonatal Rats
Author Affiliations & Notes
  • L. Mutapcic
    Mayo Medical School,
    Mayo Clinic College of Medicine, Rochester, MN
  • S.M. Wren
    Department of Ophthalmology,
    Mayo Clinic College of Medicine, Rochester, MN
  • D.A. Leske
    Department of Ophthalmology,
    Mayo Clinic College of Medicine, Rochester, MN
  • M.P. Fautsch
    Department of Ophthalmology,
    Mayo Clinic College of Medicine, Rochester, MN
  • J.M. Holmes
    Department of Ophthalmology,
    Mayo Clinic College of Medicine, Rochester, MN
  • Footnotes
    Commercial Relationships  L. Mutapcic, None; S.M. Wren, None; D.A. Leske, None; M.P. Fautsch, None; J.M. Holmes, None.
  • Footnotes
    Support  NIH Grant EY12798 and RPB Inc.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4106. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Mutapcic, S.M. Wren, D.A. Leske, M.P. Fautsch, J.M. Holmes; The Effect of L–Thyroxine Supplementation on Retinal Vascular Development in Neonatal Rats . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4106.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Hypothyroidism has been suggested as a risk factor for retinopathy of prematurity (ROP). L–Thyroxine (T4) supplementation in premature infants is controversial, but has been associated with accelerated neuroretinal development in neonatal animals. The neonatal rat retina is incompletely vascularized at birth, providing a model for the human premature infant retina. We hypothesized that T4 supplementation would accelerate vascular development of normal neonatal rat retina. Methods: 220 Sprague Dawley rats were raised in litters of 10 in room air and received either 0.05 µg/g, 0.5 µg/g, or 1.0 µg/g of intraperitoneal T4 or saline control beginning on day 1 of life for 3 days, 7 days, or 3 days followed by 4 days recovery. Rats were sacrificed on either day 4 or day 8 of life. Left eyes were fixed, retinae dissected and ADPase–stained. Flatmounted retinae were digitized and total retinal areas and retinal vascular density were evaluated in a masked manner. Serum TSH was also measured in each group at each time point. Results: Vascularized retinal area was reduced in animals receiving 1 µg/g T4 for 3 days followed by 4 days recovery compared to saline controls (85 ± 6% vs. 92 ± 3%, p=0.002). Retinal vascular density was also reduced in animals receiving daily 1 µg/g T4 compared to saline controls at both day 4 (16.8 ± 1.4 vessels/mm vs. 18.3 ± 1.3 vessels/mm, p=0.04) and day 8 (14.4 ± 1.3 vessels/mm vs. 16.8 ± 1.1 vessels/mm, p=0.0006). However, retinal vascular density returned to normal, following 4 days of recovery. At lower doses of T4 (0.05 µg/g and 0.5 µg/g for 3 or 7 days) and at 1 µg/g T4 for 7 days, there was no effect on vascularized retinal area. Serum TSH was suppressed in all T4 groups following 7 days of treatment and 3 days of treatment followed by recovery. Conclusions: Systemic T4 supplementation at 1 µg/g per day was detrimental to retinal vascular development in neonatal animals. If these effects are paralleled in human neonates, T4 supplementation might increase, rather than decrease, the risk of developing ROP. Further work on the role of T4 in the pathogenesis of ROP is warranted.

Keywords: retinopathy of prematurity • retinal neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×